DuoGenic StemCells (ROCO:7607) Debt-to-EBITDA : -0.74 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is DuoGenic StemCells Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

DuoGenic StemCells's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$31.97 Mil. DuoGenic StemCells's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$3.84 Mil. DuoGenic StemCells's annualized EBITDA for the quarter that ended in Dec. 2024 was NT$-48.20 Mil. DuoGenic StemCells's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was -0.74.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for DuoGenic StemCells's Debt-to-EBITDA or its related term are showing as below:

ROCO:7607' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.67 Med: -0.14 Max: -0.08
Current: -0.67

During the past 4 years, the highest Debt-to-EBITDA Ratio of DuoGenic StemCells was -0.08. The lowest was -0.67. And the median was -0.14.

ROCO:7607's Debt-to-EBITDA is ranked worse than
100% of 284 companies
in the Biotechnology industry
Industry Median: 1.54 vs ROCO:7607: -0.67

DuoGenic StemCells Debt-to-EBITDA Historical Data

The historical data trend for DuoGenic StemCells's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DuoGenic StemCells Debt-to-EBITDA Chart

DuoGenic StemCells Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Debt-to-EBITDA

-0.08

-0.10

-0.19

-0.67

DuoGenic StemCells Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-EBITDA	Get a 7-Day Free Trial			-0.09	-0.14	-0.19	-0.12	-0.74

Competitive Comparison of DuoGenic StemCells's Debt-to-EBITDA

For the Biotechnology subindustry, DuoGenic StemCells's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DuoGenic StemCells's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where DuoGenic StemCells's Debt-to-EBITDA falls into.

Save Embed

;

Save Embed

;

DuoGenic StemCells Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

DuoGenic StemCells's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(31.973	+	3.835)	/	-53.775
	=	-0.67

DuoGenic StemCells's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(31.973	+	3.835)	/	-48.202
	=	-0.74

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2024) EBITDA data.

DuoGenic StemCells (ROCO:7607) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

DuoGenic StemCells Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of DuoGenic StemCells's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

DuoGenic StemCells Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DuoGenic StemCells Corp (ROCO:7607) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Room R207, Innovation Incubation Center, 145, Xingda Road, South District, Taichung, TWN

Website

https://www.dgsc.com.tw

DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.

DuoGenic StemCells Headlines

No Headlines